Daphne Quimi - Net Worth and Insider Trading
Daphne Quimi Net Worth
The estimated net worth of Daphne Quimi is at least $4 Million dollars as of 2024-11-13. Daphne Quimi is the CFO of Amicus Therapeutics Inc and owns about 398,532 shares of Amicus Therapeutics Inc (FOLD) stock worth over $4 Million. Daphne Quimi is the Director of Amylyx Pharmaceuticals Inc and owns about 5,000 shares of Amylyx Pharmaceuticals Inc (AMLX) stock worth over $31,175. Daphne Quimi is also the Director of Century Therapeutics Inc and owns about 5,000 shares of Century Therapeutics Inc (IPSC) stock worth over $7,050. Details can be seen in Daphne Quimi's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Daphne Quimi has not made any transactions after 2024-09-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Daphne Quimi
Daphne Quimi Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Daphne Quimi owns 3 companies in total, including Amicus Therapeutics Inc (FOLD) , Amylyx Pharmaceuticals Inc (AMLX) , and Century Therapeutics Inc (IPSC) .
Click here to see the complete history of Daphne Quimi’s form 4 insider trades.
Insider Ownership Summary of Daphne Quimi
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
FOLD | Amicus Therapeutics Inc | 2023-01-18 | Chief Financial Officer |
AMLX | Amylyx Pharmaceuticals Inc | 2024-05-15 | director |
IPSC | Century Therapeutics Inc | 2024-09-12 | director |
Daphne Quimi Latest Holdings Summary
Daphne Quimi currently owns a total of 3 stocks. Among these stocks, Daphne Quimi owns 398,532 shares of Amicus Therapeutics Inc (FOLD) as of January 18, 2023, with a value of $4 Million and a weighting of 99.09%. Daphne Quimi owns 5,000 shares of Amylyx Pharmaceuticals Inc (AMLX) as of May 15, 2024, with a value of $31,175 and a weighting of 0.74%. Daphne Quimi also owns 5,000 shares of Century Therapeutics Inc (IPSC) as of September 12, 2024, with a value of $7,050 and a weighting of 0.17%.
Latest Holdings of Daphne Quimi
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
FOLD | Amicus Therapeutics Inc | 2023-01-18 | 398,532 | 10.49 | 4,180,601 |
AMLX | Amylyx Pharmaceuticals Inc | 2024-05-15 | 5,000 | 6.24 | 31,175 |
IPSC | Century Therapeutics Inc | 2024-09-12 | 5,000 | 1.41 | 7,050 |
Holding Weightings of Daphne Quimi
Daphne Quimi Form 4 Trading Tracker
According to the SEC Form 4 filings, Daphne Quimi has made a total of 8 transactions in Amicus Therapeutics Inc (FOLD) over the past 5 years, including 0 buys and 8 sells. The most-recent trade in Amicus Therapeutics Inc is the sale of 11,923 shares on January 18, 2023, which brought Daphne Quimi around $152,495.
According to the SEC Form 4 filings, Daphne Quimi has made a total of 1 transactions in Amylyx Pharmaceuticals Inc (AMLX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Amylyx Pharmaceuticals Inc is the acquisition of 5,000 shares on May 15, 2024, which cost Daphne Quimi around $9,450.
According to the SEC Form 4 filings, Daphne Quimi has made a total of 1 transactions in Century Therapeutics Inc (IPSC) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Century Therapeutics Inc is the acquisition of 5,000 shares on September 12, 2024, which cost Daphne Quimi around $7,650.
Insider Trading History of Daphne Quimi
- 1
Daphne Quimi Trading Performance
GuruFocus tracks the stock performance after each of Daphne Quimi's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Daphne Quimi is 18.68%. GuruFocus also compares Daphne Quimi's trading performance to market benchmark return within the same time period. The performance of stocks bought by Daphne Quimi within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Daphne Quimi's insider trading performs compared to the benchmark.
Performance of Daphne Quimi
Daphne Quimi Ownership Network
Ownership Network List of Daphne Quimi
Ownership Network Relation of Daphne Quimi
Daphne Quimi Owned Company Details
What does Amicus Therapeutics Inc do?
Who are the key executives at Amicus Therapeutics Inc?
Daphne Quimi is the Chief Financial Officer of Amicus Therapeutics Inc. Other key executives at Amicus Therapeutics Inc include director & President and CEO Bradley L Campbell , director & Executive Chairman John F Crowley , and Chief People Officer David Michael Clark .
Amicus Therapeutics Inc (FOLD) Insider Trades Summary
Over the past 18 months, Daphne Quimi made no insider transaction in Amicus Therapeutics Inc (FOLD). Other recent insider transactions involving Amicus Therapeutics Inc (FOLD) include a net sale of 232,762 shares made by Bradley L Campbell , a net sale of 333,235 shares made by John F Crowley , and a net sale of 95,000 shares made by Ellen Rosenberg .
In summary, during the past 3 months, insiders sold 30,401 shares of Amicus Therapeutics Inc (FOLD) in total and bought 0 shares, with a net sale of 30,401 shares. During the past 18 months, 803,781 shares of Amicus Therapeutics Inc (FOLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 803,781 shares.
Amicus Therapeutics Inc (FOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.
Amicus Therapeutics Inc Insider Transactions
Daphne Quimi Mailing Address
Above is the net worth, insider trading, and ownership report for Daphne Quimi. You might contact Daphne Quimi via mailing address: C/o Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury Nj 08512.